Links to All Articles Mentioned:
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-riskshttps://www.fda.gov/media/174456/downloadRFK Jr. just appeared on the Joe Rogan podcast and peptides were front and center. Dr. Matt Kaeberlein breaks down the conversation in real time, fact-checking claims about peptide efficacy, FDA regulation, and the growing black market for compounded peptides.What does the science actually say? What did RFK get right and where did the conversation miss the mark? Dr. Kaeberlein cuts through the noise with a scientist's lens, covering everything from BPC-157 to GLP-1 agonists to the FDA's Category 2 bulk drug substances list.If you're navigating the peptide space and want clarity over hype, this one's for you.Timestamps:00:00 — Intro & Episode Overview01:06 — RFK on Joe Rogan: The Peptide Conversation Begins02:06 — First Fact Check: "We Know Peptides Work"03:50 — GLP-1 Agonists: The Exception, Not the Rule05:05 — RFK's Personal Peptide Experience06:32 — The FDA's Bulk Drug Substances List Explained08:32 — FDA Category 2: What It Actually Means09:21 — The Peptides That Were Banned From Compounding10:18 — Did the FDA Consider Safety? Here's What the Data Says12:03 — Real Cases of People Harmed by Compounded Peptides13:40 — Can the FDA Consider Efficacy? Reading Directly From the Guidelines15:44 — The Peptide Black Market: How It Emerged17:54 — Will Reversing the Ban Actually Fix the Problem?19:20 — RFK's Push to Move 14 Peptides Back to the Bulk List20:16 — Dr. Kaeberlein's Take: Informed Patient Access Matters21:51 — Who Created the Black Market?22:46 — What Would Actually Help: Funding Real Clinical Trials23:36 — Final Thoughts & Call to Action
